Relationship of erosive gastritis to the acid secreting area and intestinal metaplasia, and the healing effect of pirenzepine.

Tatsuta, Masaharu; Okuda, Shujiro

doi:10.1136/gut.28.5.561

Cited by 5 publications

(6 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding indicates that antral verrucous gastritis may comprise a large proportion of EEG in this study. Because Tatsuta et al [32] reported that erosive gastritis in the antrum was associated with high gastric acid output, this finding again supports our speculation that EEG in this study might partially be acid-related. However, further investigations are necessary to confirm this speculation.…”

Section: Discussionsupporting

confidence: 90%

Lower Serum Level of Adiponectin Is Associated with Increased Risk of Endoscopic Erosive Gastritis

et al. 2011

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 90%

Lower Serum Level of Adiponectin Is Associated with Increased Risk of Endoscopic Erosive Gastritis

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Despite still being unclear, the pathogenesis of erosive gastritis appears to be caused by disruptions of normal mucosal defense mechanism and reduced gastric mucosal blood flow caused by various endogenous and exogenous pathogenic factors, including gastric acid and pepsin. Gastric erosions may also be linked with H. pylori infection, drug stimulation, obesity, high body mass index, and bile reflux [ 9 , 10 , 31 – 33 ]. As has been reported, H. pylori infection, allergic respiratory diseases, high levels of work-related stress, irregular meals, spicy food consumption, pickled food consumption in older people, and excessive smoking in men all have been positively correlated with this condition’s incidence [ 34 ].…”

Section: Discussionmentioning

confidence: 99%

“…Chronic erosive gastritis is characterized endoscopically by multiple small flat or tiny elevated lesions without or with central depressions or erosions surrounding the antrum [ 8 ]. Gastric acid was considered the primary factor in causing this condition [ 9 , 10 ], and, more recently, antral erosion predicted hyperchlorhydria in those with H. pylori negative gastritis [ 11 ]. Thus, as stated in “ Chinese consensus on chronic gastritis (2017, Shanghai) ” [ 12 ], antacids and acid-suppressing medications are recommended in order to heal mucosal erosion in the stomach and eliminate associated symptoms.…”

Section: Introductionmentioning

confidence: 99%

Chinese herbal compound prescriptions combined with Chinese medicine powder based on traditional Chinese medicine syndrome differentiation for treatment of chronic atrophic gastritis with erosion: a multi-center, randomized, positive-controlled clinical trial

Zhang

et al. 2022

Chin Med

View full text Add to dashboard Cite

Background In this study, Chinese herbal compound prescriptions combined with Chinese medicine powder were evaluated for the treatment of chronic atrophic gastritis with erosion. Methods This multi-center, randomized, positive drug control clinical trial randomly assigned 216 patients with chronic atrophic gastritis with erosion to three groups: (1) control group: aluminum plus magnesium suspension thrice per day for 4 weeks; (2) test group 1: Chinese herbal compound prescriptions twice a day plus Sanqi (Panax notoginseng) powder twice a day for 4 weeks; (3) test group 2: Chinese herbal compound prescriptions twice a day plus Sanqi (Panax notoginseng) powder and Zhebeimu (Fritillaria thunbergii Miq.) powder twice a day for 4 weeks. The primary endpoint (improvement of gastric mucosal erosion; improvement of gastric mucosal pathology) and secondary endpoints (improvement of clinical symptoms scores; improvement of the patient-reported outcome [PRO] instrument for chronic gastrointestinal diseases) were assessed using endoscopy at week 4 following the treatment. Drug-related adverse events (AEs) and adverse drug reactions (ADRs) were also compared. Results The final analysis included 202 patients (control group, 63; test group 1, 69; test group 2, 70). At week 4, using within-group comparison, gastric mucosal erosion improved in each group following treatment with a significant difference (P < 0.05); there were no statistically significant differences in gastric mucosal erosion scores among the groups after treatment (P > 0.05); in terms of improvement of gastric mucosal erosion, the efficacy rate of the control group was 69.12%, the efficacy rate of the test group 1 was 73.24%, and the efficacy rate of the test group 2 was 69.01% and efficacy rate among the groups was not statistically significant (P > 0.05). As determined by acute inflammation, chronic inflammation, atrophy, intestinal metaplasia, and dysplasia, the pathological score (total score and the highest score) did not differ statistically among groups following treatment (P > 0.05); within the control group, the total scores of acute inflammation, chronic inflammation, atrophy, and intestinal metaplasia were significantly decreased (P < 0.05), but there was no significant improvement in dysplasia (P > 0.05); in the test group 1, chronic inflammation, atrophy, and intestinal metaplasia and dysplasia scores were significantly decreased (P < 0.05), but acute inflammation did not improve (P > 0.05); there was a significant reduction in the atrophy score in test group 2 (P < 0.05), but no improvement in the scores of acute inflammation, chronic inflammation, intestinal metaplasia, and dysplasia was observed (P > 0.05). Similarly, within the control group, the highest scores of acute inflammation, chronic inflammation, atrophy, and intestinal metaplasia were significantly decreased (P < 0.05), but there was no significant improvement in dysplasia (P > 0.05); there was a significant reduction in highest scores of atrophy, intestinal metaplasia, and dysplasia (P < 0.05) in test group 1, but the highest scores didn’t not improve with acute inflammation and chronic inflammation (P > 0.05); there was a significant reduction in the highest atrophy score in test group 2 (P < 0.05), but no improvement in the highest scores of acute inflammation, chronic inflammation, intestinal metaplasia, and dysplasia was observed (P > 0.05). Compared to the control group, the main symptom scores and total symptom scores in the test groups were lower following treatment, with a statistically significant difference (P < 0.05); the analysis of covariance with center, erosion type, and group as factors was applied, and the comparison among the groups in dyspepsia, defecation, and total PRO instrument scores were statistically significant (P < 0.05). In the study period, AEs were reported in 3 (4.23%) patients in the test group 1 and 3 (4.41%) patients in the control group; ADRs were confirmed in 3 (4.23%) patients from the test group 1 and 2 (2.94%) from the control group. AEs and ADRs were not statistically significantly different among groups (AE, P = 0.2213; ADR, P = 0.2872). No serious AE or ADR was reported. Conclusions This study has shown that both aluminum plus magnesium suspension and Chinese herbal compound prescriptions together with Panax notoginseng powder are capable of improving gastric mucosal erosion and reducing gastric mucosal pathological scores, and there were no statistically significant differences among the groups in primary endpoints, indicating that Chinese herbal therapy can achieve similar efficacy than antacids in terms of primary outcomes. The aluminum plus magnesium suspension is comparable to Chinese herbal therapy in improving atrophy and intestinal metaplasia, and is inferior to Chinese herbal therapy in improving dysplasia. In addition, the Chinese herbal therapy significantly outperforms the aluminum plus magnesium suspension in improving symptoms. Therefore, the overall clinical outcome of Chinese herbal compound prescriptions together with Panax notoginseng powder based on TCM syndrome patterns in the treatment of erosive gastritis is superior to that of antacids. Trial registration ChiCTR, ChiCTR-IPR-15005905. Registered 22 January 2015, https://www.chictr.org.cn/showproj.aspx?proj=10359

show abstract

“…In contrast, our study showed a negative relationship between VG and H. pylori infection. Gastric acid was considered the predominant factor in the genesis of erosive gastritis [ 2 , 11 ] and, recently, antral erosion was reported to predict hyperchlorhydria in H. pylori negativity [ 12 ]. Obesity and high BMI were also associated with gastric erosions [ 3 , 4 , 13 , 14 ].…”

Section: Discussionmentioning

confidence: 99%

Verrucous antral gastritis in relation to Helicobacter pylori infection, nutrition, and gastric atrophy

Tsuji

Umehara

Takenaka

et al. 2019

Gastroenterology Report

View full text Add to dashboard Cite

Background There have been few studies in the English literature regarding verrucous gastritis (VG). The present study investigated the clinical and endoscopic features of verrucous antral gastritis, especially focusing on Helicobacter pylori infection, nutrition, and gastric atrophy. Methods We performed a retrospective study of patients who underwent routine endoscopy with indigo carmine chromoendoscopy and a comparative study was conducted between VG-positive and VG-negative groups. VG was subdivided into classical and numerous types based on the number and distribution of verrucous lesions. Demographic, clinical, and endoscopic data including body mass index (BMI), serum albumin and cholesterol, gastric atrophy, reflux oesophagitis, Barrett’s oesophagus, and H. pylori status were collected. Univariate and multivariable analyses were performed to identify factors associated with VG. Results We analysed the data of 621 patients undergoing routine endoscopy and found that VG (n = 352) was significantly associated with increased BMI (1.12 [1.05–1.18], P < 0.01), reflux esophagitis (1.96 [1.10–3.28], P < 0.01), and H. pylori negativity with or without a history of eradication (9.94 [6.00–16.47] and 6.12 [3.51–10.68], P < 0.001, respectively). Numerous-type (n = 163) VG was associated with both closed- and open-type gastric atrophy (9.9 [4.04–21.37] and 8.10 [3.41–19.24], P < 0.001, respectively). There were no statistical differences between groups regarding age, sex, total cholesterol, albumin, and bile-colored gastric juice. Conclusions Verrucous antral gastritis was related to increased BMI, reflux esophagitis, and H. pylori negativity. Numerous-type verrucous lesions were associated with gastric atrophy. These indicate that VG may be a physiological phenomenon due to high gastric acidity, mechanical overload, and vulnerability of background mucosa.

show abstract

Relationship of erosive gastritis to the acid secreting area and intestinal metaplasia, and the healing effect of pirenzepine.

Cited by 5 publications

References 9 publications

Lower Serum Level of Adiponectin Is Associated with Increased Risk of Endoscopic Erosive Gastritis

Lower Serum Level of Adiponectin Is Associated with Increased Risk of Endoscopic Erosive Gastritis

Chinese herbal compound prescriptions combined with Chinese medicine powder based on traditional Chinese medicine syndrome differentiation for treatment of chronic atrophic gastritis with erosion: a multi-center, randomized, positive-controlled clinical trial

Verrucous antral gastritis in relation to Helicobacter pylori infection, nutrition, and gastric atrophy

Contact Info

Product

Resources

About